title: Response to Frederic Bretzner et al. "Target populations for first-in-human embryonic stem cell research in spinal cord injury".
abstract: We address concerns raised in this issue by Bretzner et al. (2011) by explaining the rationale for including subjects with subacute, neurologically complete spinal cord injuries in the Phase 1 trial of GRNOPC1. We also present elements of the informed consent process that minimize the likelihood of therapeutic misconception.
authors.affiliation: Geron Corporation, Menlo Park, CA 94025-1109, USA. ewirth@geron.com
authors.forename: Edward
authors.initials: E
authors.lastname: Wirth
authors.forename: Jane S
authors.initials: JS
authors.lastname: Lebkowski
authors.forename: Karen
authors.initials: K
authors.lastname: Lebacqz
mesh_terms: D000818:Animals; D035843:Biomedical Research; D017321:Clinical Trials, Phase I as Topic; D032962:Consent Forms / Q000941:ethics* / Q000331:legislation & jurisprudence; D015276:Health Care Rationing; D006801:Humans; D051188:Knowledge Bases; D023421:Models, Animal; D028701:Patient Rights; D018579:Patient Selection / Q000941:ethics*; D020127:Recovery of Function; D018570:Risk Assessment; D013119:Spinal Cord Injuries / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome